247 related articles for article (PubMed ID: 9591813)
1. Mycosis fungoides in young patients: clinical characteristics and outcome.
Crowley JJ; Nikko A; Varghese A; Hoppe RT; Kim YH
J Am Acad Dermatol; 1998 May; 38(5 Pt 1):696-701. PubMed ID: 9591813
[TBL] [Abstract][Full Text] [Related]
2. Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides.
Chinn DM; Chow S; Kim YH; Hoppe RT
Int J Radiat Oncol Biol Phys; 1999 Mar; 43(5):951-8. PubMed ID: 10192339
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides.
Kim YH; Chow S; Varghese A; Hoppe RT
Arch Dermatol; 1999 Jan; 135(1):26-32. PubMed ID: 9923777
[TBL] [Abstract][Full Text] [Related]
4. Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis.
Kim YH; Jensen RA; Watanabe GL; Varghese A; Hoppe RT
Arch Dermatol; 1996 Nov; 132(11):1309-13. PubMed ID: 8915308
[TBL] [Abstract][Full Text] [Related]
5. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience.
Kim YH; Martinez G; Varghese A; Hoppe RT
Arch Dermatol; 2003 Feb; 139(2):165-73. PubMed ID: 12588222
[TBL] [Abstract][Full Text] [Related]
6. The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides.
Navi D; Riaz N; Levin YS; Sullivan NC; Kim YH; Hoppe RT
Arch Dermatol; 2011 May; 147(5):561-7. PubMed ID: 21576575
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression.
Kim YH; Liu HL; Mraz-Gernhard S; Varghese A; Hoppe RT
Arch Dermatol; 2003 Jul; 139(7):857-66. PubMed ID: 12873880
[TBL] [Abstract][Full Text] [Related]
8. Mycosis fungoides: management with topical nitrogen mustard.
Hoppe RT; Abel EA; Deneau DG; Price NM
J Clin Oncol; 1987 Nov; 5(11):1796-803. PubMed ID: 3681368
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of a polymerase chain reaction-detectable dominant T-lymphocyte clone in cutaneous lesions of patients with mycosis fungoides.
Delfau-Larue MH; Dalac S; Lepage E; Petrella T; Wechsler J; Farcet JP; Bagot M
Blood; 1998 Nov; 92(9):3376-80. PubMed ID: 9787176
[TBL] [Abstract][Full Text] [Related]
10. Survival, disease progression and prognostic factors in elderly patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of 174 patients.
Lebowitz E; Geller S; Flores E; Pulitzer M; Horwitz S; Moskowitz A; Kheterpal M; Myskowski PL
J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):108-114. PubMed ID: 30176169
[TBL] [Abstract][Full Text] [Related]
11. Mechlorethamine gel for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma.
Talpur R; Venkatarajan S; Duvic M
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):591-7. PubMed ID: 25068889
[TBL] [Abstract][Full Text] [Related]
12. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
13. Topical nitrogen mustard therapy in patients with mycosis fungoides or parapsoriasis.
Lindahl LM; Fenger-Gron M; Iversen L
J Eur Acad Dermatol Venereol; 2013 Feb; 27(2):163-8. PubMed ID: 22229501
[TBL] [Abstract][Full Text] [Related]
14. A case-control study of clinicopathologic features, prognosis, and therapeutic responses in patients with granulomatous mycosis fungoides.
Li JY; Pulitzer MP; Myskowski PL; Dusza SW; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2013 Sep; 69(3):366-74. PubMed ID: 23685027
[TBL] [Abstract][Full Text] [Related]
15. Ultimate results of radiation therapy for T1-T2 mycosis fungoides (including reirradiation).
Ysebaert L; Truc G; Dalac S; Lambert D; Petrella T; Barillot I; Naudy S; Horiot JC; Maingon P
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1128-34. PubMed ID: 15001254
[TBL] [Abstract][Full Text] [Related]
16. Secondary cancers, comorbidities and mortality associated with nitrogen mustard therapy in patients with mycosis fungoides: a 30-year population-based cohort study.
Lindahl LM; Fenger-Grøn M; Iversen L
Br J Dermatol; 2014 Mar; 170(3):699-704. PubMed ID: 24024659
[TBL] [Abstract][Full Text] [Related]
17. Juvenile mycosis fungoides: cutaneous T-cell lymphoma with frequent follicular involvement.
Hodak E; Amitay-Laish I; Feinmesser M; Davidovici B; David M; Zvulunov A; Pavlotsky F; Yaniv I; Avrahami G; Ben-Amitai D
J Am Acad Dermatol; 2014 Jun; 70(6):993-1001. PubMed ID: 24629999
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics, prognostic factors, and survival of 393 patients with mycosis fungoides and Sézary syndrome in the southeastern United States: a single-institution cohort.
Desai M; Liu S; Parker S
J Am Acad Dermatol; 2015 Feb; 72(2):276-85. PubMed ID: 25458019
[TBL] [Abstract][Full Text] [Related]
19. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up.
Herrmann JJ; Roenigk HH; Hurria A; Kuzel TM; Samuelson E; Rademaker AW; Rosen ST
J Am Acad Dermatol; 1995 Aug; 33(2 Pt 1):234-42. PubMed ID: 7622650
[TBL] [Abstract][Full Text] [Related]
20. Unusual variants of mycosis fungoides.
Abeldaño A; Arias M; Benedetti A; Ochoa K; Maskin M; Pellerano G; Kien MC; Chouela E
Skinmed; 2011; 9(4):218-22. PubMed ID: 21980706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
